Albumin-bound paclitaxel: The benefit of this new formulation in the treatment of various cancers

Journal of Chemotherapy

Volumn 23, Issue 2, 2011, Pages 59-66

  Montana, M ^a   Ducros, C ^a   Verhaeghe, P ^a   Terme, T ^a   Vanelle, P ^a,b   Rathelot, P ^a,b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

Author keywords

Albumin bound paclitaxel; Lung cancer; Melanoma; Metastatic breast cancer; Paclitaxel; Pancreatic cancer

Indexed keywords

ALBUMIN; BEVACIZUMAB; CARBOPLATIN; CREMOPHOR; DACARBAZINE; DOCETAXEL; GEMCITABINE; NANOPARTICLE; OSTEONECTIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADVANCED CANCER; AREA UNDER THE CURVE; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CAVEOLA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FEBRILE NEUTROPENIA; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MELANOMA; MICELLIZATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVARY CARCINOMA; PANCREAS CANCER; PARTICLE SIZE; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; RECURRENT CANCER; REVIEW; SENSORY NEUROPATHY; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA;

EID: 80052693968     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2011.23.2.59     Document Type: Review

References (67)

1. Miller K, Neilan B, Sze DM. Development of Taxol and other endo-phyte produced anti-cancer agents. Recent Pat Anticancer Drug Discov 2008; 3 (1): 14-19.
2. Adams JD, Flora KP, Goldspiel BR, Wilson JW, Arbuck SG, Finley R. Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst Monogr 1993; 15: 141-147.
3. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990;82(15):1247-1259.
4. Aapro MS, Von Minckwitz G. Molecular basis for the development for novel taxanes in the treatment of metastatic breast cancer. Eur J Cancer 2008; 6 (10): 3-11.
5. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990; 8 (7): 1263-1268.
6. Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002; 235 (1-2): 179-192.
7. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL. The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37 (13): 1590-1598.
8. Kloover JS, den Bakker MA, Gelderblom H, van Meerbeeck JP. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer 2004; 90 (2): 304-305.
9. Mass B, Huber C, Kramer I. Plasticizer extraction of Taxol infusion solution from various infusion devices. Pharm World Sci 1996; 18 (2): 78-82.
10. Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999; 59 (7): 1454-1457.
11. Piccart M. Nab-paclitaxel: a targeted chemotherapy to improve out-comes in metastatic breast cancer. Asia-Pacific J Oncol Hematol 2009; 1(1): 5-12.
12. van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 1999; 81(2): 330-335.
13. Ten Tije Aj, Verweij J, Loos WJ, Sparreboom A. Pharmacological ef- fects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003; 42 (7): 665-685.
14. Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 2004; 22 (11): 2061-2068.
15. Foote M. Using nanotechnology to improve the characteristics of an-tineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel. Biotechnol Annu Rev 2007; 13: 345-357.
16. Stinchcombe TE. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel. Nanomedicine (Lond) 2007; 2 (4): 415-423.
17. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. Increased an- titumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006; 12 (4): 1317-1324.
18. Purcell M, Neault JF, Tajmir-Riahi HA. Interaction of taxol with human serum albumin. Biochim Biophys Acta 2000; 1478 (1): 61-68.
19. Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 2008; 60 (8): 876-885.
20. Paal K, Muller J, Hegedus L. High affinity binding of paclitaxel to human serum albumin. Eur J Biochem 2001; 268 (7): 2187-2191.
21. Desai N, Trieu V, Damascelli B, Soon-Shiong P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol 2009; 2 (2): 59-64.
22. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002; 8 (5): 1038-1044.
23. Agence Fran£aise de Securite Sanitaire et des Produits de Sante, Avail-able from URL: http://afssaps- prd.afssaps.fr/php/ecodex/frames.php?specid=61347058&typedoc=R&ref=R0089587.htm [Accessed 2010 Jul 10],
24. Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A. et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 2005;11 (11): 4136-4143.
25. Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 2008; 14 (13): 4200-4205.
26. Blum JL, Savin MA, Edelman G, Pippen JE, Robert NJ, Geister BV, et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 2007; 7 (11): 850-856.
27. Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001; 19 (22): 4216-4223.
28. Valero V, Jones SE, Von Hoff DD, Booser DJ, Mennel RG, Ravdin PM, et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998; 16 (10): 3362-3368.
29. Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC, et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol. 2005; 23 (25): 6019-6026.
30. Tubiana-Hulin M. How to maximize the efficacy of taxanes in breast cancer. Cancer Treat Rev 2005; 31 (4): S3-9.
31. Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, et al. Significantly longer progression-free survival with nabpaclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009; 27 (22): 3611-3619.
32. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23 (31): 7794-7803.
33. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
34. Conlin AK, Hudis CA, Bach A, et al. Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer. Proc ASCO 2009: Abstract 1006.
35. Link JS, Waisman JR, Nguyen B, Jacobs CI. Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer. Clin Breast Cancer 2007; 7 (10): 779-783.
36. Jones J, Takeda A, Tan SC, Cooper K, Loveman E, Clegg A. Gem-citabine for the treatment of metastatic breast cancer. Health Technol Assess 2009; 13 (2): 1-7.
37. Roy V, LaPlant BR, Gross GG, Bane CL, Palmieri FM; North Central Cancer Treatment Group. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol 2009; 20 (3): 449-53.
38. Surveillance Epidemiology and End Results Available from URL: http://seer.cancer.gov/statistics/ [Accessed the 2010 Jul 10].
39. Mayer EL, Burstein HJ. Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am 2007; 21 (2): 257-72.
40. Conlin AK, Seidman AD. Taxanes in breast cancer: an update. Curr Oncol Rep 2007; 9 (1): 22-30.
41. Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 2007; 4: CD004421.
42. Friedrich M, Diesing D, Villena-Heinsen C, Felberbaum R, Kolberg HC, Diedrich K. Taxanes in the first-line chemotherapy of metastatic breast cancer: review. Eur J Gynaecol Oncol 2004; 25 (1): 66-70.
43. Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 2001; 6 (2): 133-146.
44. Abraham J. Nab-paclitaxel as first line therapy for metatstatic breast cancer. Commun Oncol 2008; 5 (7): 1-7.
45. Mitchell PL, Basser R, Chipman M, Grigg A, Mansfield R, Cebon J; et al. A phase II study of escalated-dose docetaxel with granulocyte colony stimulating factor support in patients with advanced breast cancer. Ann Oncol 2004; 15 (4): 585-589.
46. Harvey V, Mouridsen H, Semiglazov V, Jakobsen E, Voznyi E, Robinson BA, et al. Phase III trial comparing three doses of docetaxel for second line treatment of advanced breast cancer. J Clin Oncol 2006; 24 (31): 4963-4970.
47. European Medicine Agency Available from URL: http://www.ema. europa. eu/humandocs/PDFs/EPAR/abraxane/H-778-PI-en.pdf [Accessed 2010 Jun 16].
48. Socinski MA. Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer. Oncologist 1999; 4 (5): 408-416.
49. Fumoleau P. Efficacy and safety of docetaxel in clinical trials. Am J Health Syst Pharm 1997; 54 (24): S19-24.
50. Ranson M, Davidson N, Nicolson M, Falk S, Carmichael J, Lopez P, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000; 92 (13): 1074-1080.
51. Roszkowski K, Pluzanska A, Krzakowski M, Smith AP, Saigi E, Aasebo U, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-na'ive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000; 27 (3): 145-157.
52. Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, Bhar P, et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006; 17 (8): 1263-1268.
53. Rizvi NA, Riely GJ, Azzoli CG, Miller VA, Ng KK, Fiore J, et al. Phase l/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol 2008; 26 (4): 639-643.
54. Belani CP, Barstis J, Perry MC, La Rocca RV, Nattam SR, Rinaldi D, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003; 21 (15): 2933-2939.
55. Alierton JP, Hagenstad CT, Webb RT, Smith GB, Birch R, Goggins TF, et al. A phase II evaluation of the combination of paclitaxel protein bound and carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006; 24 (18S): 7127.
56. Socinski MA, Bondarenko IN, Karaseva NA, Makhson A, I. Vynnychenko I, I. Okamoto I, et al. Results of a randomized, phase III trial of nab paclitaxel and carboplatin compared with cremophor-based paclitaxel and carboplatin as first-line therapy in advanced non-small-cell lung cancer. ASCO Annual 2010: Abstract LBA7511.
57. Reynolds C, Ban-era D, Jotte R, Spira Al, Weissman C, Boehm KA, et al. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-smail cell lung cancer. J Thorac Oncol 2009; 4 (12): 1537-1543.
58. Hersh EM, O'Day SJ, Ribas A, Samlowski WE, Gordon MS, Shechter DE, et al. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer 2010; 116 (1): 155-163.
59. Gogas H, Bafaloukos D, Bedikian AY. The role of taxanes in the treatment of metastatic melanoma. Melanoma Res 2004; 14 (5): 415-420.
60. Bedikian AY, Milkvard M, Pehamberger H, Conry R, Gore M, Trefzer U, et al. Melanoma Study Group. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24 (29): 4738-4745.
61. Masellis AM, Sielaff TD, Bender GP. Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens. Int J Clin Oncol 2009; 14 (5): 478-81.
62. Von Hoff DD, Ramanathan R, Borad M, Laheru D, Smith L, Wood T, et al. SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study. J Clin Oncol 2009; 27 (15): Abstract 4525.
63. Hosein PJ, Lopes GD Jr., Gomez CM, Pastorini VH, Macintyre J, Easey M, et al. A phase II trial of nab-paclitaxel (NP) in patients with advanced pancreatic cancer (PC) who have progressed on gemcitabine (G)- based therapy. J Clin Oncol 2010; 28(15): Abstract 4120.
64. Boruta DM 2nd, Fowler WC Jr, Gehrig PA, Boggess JF, Walton LA, Van Le L. Weekly paclitaxel infusion as salvage therapy in ovarian cancer. Cancer Invest. 2003; 21 (5): 675-681.
65. Teneriello MG, Tseng PC, Crozier M, Encamacion C, Hancock K, Messing MJ, et al. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol 2009; 27 (9): 1426-1431.
66. Coleman RL, Brady W, McMeekin DS, Rose PG, Soper JT, Lentz SS, et al. A phase II evaluation of nab-paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group (GOG) study. J Clin Oncol 2010; 28 (15): Abstract 5010.
67. T. D. Tillmanns, M. P. Lowe, L. S. Schwartzberg, M. S. Walker, E. J. Stepanski. A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. J Clin Oncol 2010; 28: (15): Abstract 5009.